* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Admissions:
None
Delistings:
None
What’s baking in the oven?
It's a little empty
Banquet Buffet****
Corero Network Security 8.75p £42.25m (CNS.L)
The distributed denial of service protection specialists and champion of adaptive, real-time service availability, updated on trading for the six months ended 30 June. Corero delivered strong financial progress across H1 2026, underpinned by a 14% increase in Order Intake to $14.3m (H1 2025: $12.5m), and a combination of new customer wins and expanded contracts with existing customers. In addition, the Company experienced high renewal rates of 96% for its multi-year, subscription-based and DDoS Protection as-a-Service products. The Company reported substantial revenue growth in the Period, increasing by 42% to $15.5m (H1 2025: $10.9m). This was driven by a combination of the 2025 ARR providing revenue visibility in 2026, renewals and upsells with existing customers and continued new customer wins. The Group expects to report a significant improvement in EBITDA for H1 2026 to approximately $2.6m (H1 2025: loss $1.4m), with adjusted EBITDA of $2.7m (H1 2025: loss $1.3m) excluding share-based payments.
Digitalbox 5.25p £7.43m (DBOX.L)
The mobile-first digital media business, which owns among others the websites The Tab, The Daily Mash, The Poke and TV Guide, announces an unaudited trading update ahead of the publication of its unaudited results for the six months to 30 June on 23 September. In H1 2026, advertising performance, session values and yields have significantly improved year-on-year. Trading was strong in Q1 2026, but changes by Meta to favour creator content on its platforms created significant audience headwinds from Q2 2026 onwards. While previous algorithmic changes have typically been followed by a recovery in audience engagement as seen in June, these changes have negatively impacted the trading outlook of Digitalbox as well as its peers.
Kromek Group 8.25p £51.90m (KMK.L)
The global detection Company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, announces the successful delivery of the third milestone under its enablement agreement with Siemens Medical Solutions USA, Inc. and the grant of options to directors of the Company. Further to Kromek's announcement of 30 January 2025, the Company announced that it has successfully delivered the third milestone under its Enablement Agreement with Siemens Healthineers and has received the third payment instalment of $2.5m. To date, the Company has received $32.5m under the Enablement Agreement. The remaining payment of $5.0m is payable at completion of the Group's delivery under the Enablement Agreement, which is expected to occur in the financial year to 30 April 2029.
Nativo Resources 0.17p £2.85m (NTVO.L)*
The precious metal Company announced the publication of a research note benchmarking the Company's proposed La Patona Gold Ore Processing Plant in the Caravelí region of Peru against the five most relevant operating comparators in Peru's institutional artisanal and small-scale mining gold processing sector, alongside a market study on regional ore supply. These documents have been internally generated by the Company and published for illustrative purposes. The benchmark analysis confirms that the ore-purchasing, asset-light gold processing model generates 10-13% operating margins at scale in Peru - validated by Dynacor (US$397.6m revenue, 12.4% gross margin, 2025) and Paltarumi (~US$268m revenue, 11.6% EBITDA). La Patona's proposed 350 tpd full-build plant is designed to operate within this benchmark range, with structural advantages in feed security, governance and human capital efficiency that distinguish it from current market participants. Peru's ASM gold sector is one of the world's largest concentrations of high-grade gold extraction outside formal mine structures. The Caravelí and Chala belts of the Arequipa region alone support multiple processing plants operating at 150-500 tpd throughput, purchasing ore from hundreds of registered ASM miners and selling doré to LBMA-accredited Swiss refineries.
Pathos Communications 24.50p £15.67m (NEWS.L)
The PR technology business, announced a trading update for the half year ended 30 June, which highlighted a period of strong delivery, with revenue, profits and cash receipts all increasing as the Company benefited from the investment of the proceeds of its successful IPO. The Company reported that trading since then has continued to strengthen, with the Company delivering a record monthly revenue of over US$1.8m in July 2026 (unaudited). The growth has been driven by the enhanced Sales Team achieving new client sign-up rates that are 30% higher since its inception. This momentum further underpins management's confidence in at least meeting market expectations for the current financial year, which is for revenue of US$14.0m and Adjusted EBITDA of US$4.0m.
Shearwater Group 62.50p £14.66m (SWG.L)
The cybersecurity, advisory, and managed security services group announces that its subsidiaries Brookcourt Solutions and Pentest Limited, have both secured positions on G-Cloud 15, the UK Government's enlarged procurement framework for cloud-based software, hosting and support services. The G-Cloud 15 offering includes solutions across a broad range of cybersecurity disciplines, including identity and access management, Zero Trust, cloud security, network security, threat detection and response, vulnerability management, data protection, security operations, managed security services and AI governance. Brookcourt has increased the number of approved technologies and specialist services available through G-Cloud by c.77%, from 31 on G-Cloud 14 to 55 on G-Cloud 15. As previously announced, Brookcourt has already converted its G-Cloud 14 position into new business, most recently securing a c.£1m contract expansion with a central Government department in December 2025 for the provision of threat intelligence services.
Solvonis Therapeutics 0.15p £9.53m (SVNS.L)
The late clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system disorders announced results from the initial in vitro cardiac ion-channel and broader off-target screening of SVN-015 under the U.S. National Institute on Drug Abuse's Addiction Treatment Discovery Program. The Company previously announced SVN-015's acceptance into the ATDP in December 2025. Following review of the initial screening results, NIDA has confirmed that SVN-015 will advance into further evaluation under the ATDP. This is expected to include confirmatory transporter studies and in vivo studies to characterise the onset and duration of its pharmacological activity. SVN-015 is a proprietary discovery-stage small molecule designed to modulate key monoamine transporters, including the dopamine transporter and serotonin transporter. It is being developed initially as a potential treatment for stimulant use disorder, including cocaine and methamphetamine use disorders.
Wellnex Life 5.50p £2.37m (WNX.L)
The consumer healthcare Company has entered into a formal binding agreement to sell its "Pain Away" business and assets to Mentholatum Australasia Pty Ltd. Mentholatum is ultimately owned by Rohto Pharmaceutical Co Ltd, a Japanese FMCG and pharmaceutical company listed on the Tokyo Stock Exchange. The Transaction, which is subject to shareholder approval (amongst other customary conditions), represents an important strategic milestone for Wellnex Life, marking a defining step in the Company's transformation by converting a flagship asset into capital which will be redeployed to repay debt, strengthen the Company's balance sheet, and support the Company's focus on its retained consumer healthcare and contract manufacturing operations as well as future growth opportunities. The total maximum consideration is up to A$21.3m in cash, comprising upfront purchase price of A$19.8m payable at completion, and an earn-out of up to A$1.5m that is payable subject to threshold and target normalised EBITDA performance of the Pain Away business during the 12 months post-completion.
AQSE Market:
Global Connectivity 0.125p £0.4m (AQSE:GCON)*
The investing Company focused on strategic holdings in high-growth, connectivity-aligned technologies, has raised £293,239.00 by way of a placing of 208,239,000 new ordinary shares and subscription of 85,000,000 new Ordinary Shares at an issue price of 0.1p per share. The Issue Price is at the closing bid price of an Ordinary Share on 5 August 2026 (being the latest practicable date prior to this announcement). Net proceeds from the Fundraising will be allocated to working capital and provide the Company with the financial runway to July 2027, assuming that the Executive Chairman continues not to draw his fees in the absence of a liquidity event.
ProBiotix Health 8.00p £12.65m (AQSE:PBX)
The life sciences business developing probiotics to support cardiometabolic health announces its unaudited results for the six months to 30 June 2026. Gross revenue increased 53% to £2.06m (H1 2025: £1.34m), while gross profit increased 66% to £1.245m (H1 2025: £748k). The Company has an EBITDA profit of £151k (excluding share-based payments) and a strong cash balance of £1.244m (H1 2025: £1.3m). During the period, five new partnerships were established, with the active customer base growing by more than 15%, reflecting the growing demand for effective science-backed preventive cardiometabolic supplement products.
What’s baking in the oven?
Potential IPOs:***
Dual List:***
5th August: 1947 Oil & Gas, the newly incorporated oil and gas production company focused on acquiring, operating and growing a portfolio of producing assets in the United States, announced its intention to IPO onto AIM. In connection with Admission, the Company has entered into a conditional agreement to acquire Renaissance Offshore, LLC, a privately held, Houston-based oil and gas production company with interests in eleven fields located in the shallow-water Gulf of America. The Company is raising gross proceeds of £50m and the expected market capitalisation of the Company on Admission will be £65m. Admission is expected to occur in August 2026.
3rd August: Africa Bitcoin Corporation has announced its intention to dual list onto the AQSE Market. The company is a financial services group with a Bitcoin Treasury Strategy dedicated to providing financial services to SMEs across South Africa with a broad suite of solutions, including non-bank debt financing, novel equity linked instruments, insurance offerings and other tailored financial products.
The Company has a primary listing on the Main Board of the Johannesburg Stock Exchange and secondary listings on the A2X Proprietary Limited and the Namibia Securities Exchange and its ordinary shares also trade on OTCQB Market in the United States and the Frankfurt Stock Exchange. Expected admission date is 17th August.
Reverse Takeovers:***
4th August: Vast Resources (VAST.L), the mining exploration, development and production company, with assets in Tajikstan and Tomania, has proposed a reverse takeover of Gulf International Minerals, which holds a 49% stake in the Aprelevka JV in Tajikistan, alongside the Tajik government's 51%. The company intends to complete the transaction via an all-share consideration deal with Bay Square Pacific and its shareholders. Alongside the Acquisition, the Company has conditionally raised gross proceeds of £5.9m by way of a placing of 94,400,000 new ordinary shares and a subscription for 26,359,826 new ordinary shares, in each case at 6.25p per share. The Company also intends to launch a retail offer. The expected date of admission is 19 August 2026.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
